Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acral Lentiginous Melanoma: early-phase trial registry
1 of 5 indexed Acral Lentiginous Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Acral Lentiginous Melanoma: 5 US clinical trials tracked, 1 recruiting.
Acral Lentiginous Melanoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition acral-lentiginous-melanoma
OPEN 1 | RECR 20% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Acral Lentiginous Melanoma lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acral Lentiginous Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acral Lentiginous Melanoma is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Acral Lentiginous Melanoma research.
National Cancer Institute (NCI) accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Acral Lentiginous Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Acral Lentiginous Melanoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT04511013
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
National Cancer Institute (NCI)
NCT03698019
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
NCT00937937
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
NCT03025256
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Dana-Farber Cancer Institute
NCT00424515
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Acral Lentiginous Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acral Lentiginous Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acral Lentiginous Melanoma page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Acral Lentiginous Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Acral Lentiginous Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acral Lentiginous Melanoma condition card totals 5 registered trials; most-linked intervention Nivolumab; top US site state Arkansas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.